Pfizer, Inc. · NYSE:PFE

Pfizer — Goldman Sachs 38th Annual Global Healthcare Conference 2017

9 slides from Pfizer's conference presentation, Jun 14, 2017

  1. Slide 1: Goldman Sachs Healthcare Conference

    Goldman Sachs Healthcare Conference Mikael Dolsten M.D., Ph.D. June 14, 2017

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation includes forward-looking statements about, among other things, development of Pfizer’s products and product candidates, including their potential benefits, expected clinical trial study starts, expected regulatory submissions and approvals and anticipated

  3. Slide 3: Strong Track Record of Product Approvals

    Strong Track Record of Product Approvals 22 Key Approvals (14 NME); 42 Pivotal Study Starts (2011 – YTD) (Adult / CAPiTA) 214 Discovery Projects Phase 1 Phase 2 Phase 3 Registration 96 Discovery Projects 36 17 32 11 Total (As of May 2, 2017) Potential in 2017/18 for 15 Pivotal Studies & 10 Midsize D

  4. Slide 4: Anchor Assets

    > ANCHOR » ASSETS

  5. Slide 5: Focus: Growing In-Market Anchors

    2011-2017 1 WAVE Focus: Growing In-Market Anchors

  6. Slide 6: Focus: Delivering on Clinical Pipeline

    I&I: Oncology: Rare Disease: Next Generation I-O Combos Gene Therapy JAK inhibitors Vaccines: Internal Medicine: C. difficile, NASH, AD/PD S. aureus & Pneumo Nextgen 2018-2022 2 WAVE Focus: Delivering on Clinical Pipeline

  7. Slide 7: NMEs & Combos, Vaccines, Oncology: Potential Blockbuster Approvals

    Potential for up to 15 Blockbuster Approvals over next 5 Years Approximately half potentially receiving approval by 2020 NMEs & Combos Oncology Vaccines 1. IO-IO: Doublet / Triplet 9. Clostridium Difficile 2. IO-Targeted / IO-Chemo 10. Staphylococcus Aureus 3. Targeted Cancer Agents 11. Pneumococcal

  8. Slide 8: Potential 2017/18 News Flow

    Potential 2017/18 News Flow LATE STAGE Xeljanz ertugliflozin Bosulif Xeljanz PsA T2D CML 1L UC Action Date (US) Action Date (US) Action Date(US/EU) Action Date (US) lorlatinib ALK+ dacomitinib glasdegib + LDAC Sutent NSCLC EGFR+ NSCLC 1L AML Unfit Adjuvant RCC Submission (US) Submission(US/EU) Submi

  9. Slide 9: Questions?

    Questions?

Pfizer — Goldman Sachs 38th Annual Global Healthcare Conference 2017 on 6ix